1 / 78

Urinary Bladder Cancer

Urinary Bladder Cancer. John Crew, M.D., PGY-2 Radiation Oncology Brown Cancer Center, University of Louisville. Outline. Overview Anatomy Etiology/Epidemiology Risk Factors Pathology Clinical Presentation, Diagnosis, Work-up Staging Literature Review Conclusions Questions. Anatomy.

marty
Télécharger la présentation

Urinary Bladder Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Urinary Bladder Cancer John Crew, M.D., PGY-2 Radiation Oncology Brown Cancer Center, University of Louisville

  2. Outline • Overview • Anatomy • Etiology/Epidemiology • Risk Factors • Pathology • Clinical Presentation, Diagnosis, Work-up • Staging • Literature Review • Conclusions • Questions

  3. Anatomy

  4. Anatomy http://academic.kellogg.edu

  5. Etiology/Epidemiology • 2009 • 70,980 new cases of bladder cancer • 14,330 deaths from bladder cancer • Median age: 73 y • M:F – 3:1 • Caucasian predominance • 90% > Age 55

  6. Incidence http://www.cdc.gov

  7. http://seer.cancer.gov/

  8. http://seer.cancer.gov/

  9. Death Rates http://seer.cancer.gov/

  10. Clinical Presentation • Painless Hematuria • Intermittent, gross, painless • ~10-20% with gross hematuria/~2-5% with microscopic hematuria diagnosed with bladder cancer • Pain • Flank • Suprapubic • Hypogastric/Perineal pain • Abdominal/RUQ • Distant sites • Voiding • Functional changes/obstruction • Irritation • Constitutional • Fatigue, weight loss, anorexia, renal failure, FTT

  11. Lymph Nodes at Risk • Primary Drainage • Hypogastric • Obturator • Iliac (External, Internal, NOS) • Perivesical Pelvic, NOS • Sacral (lateral, sacral promontory (Gerota’s) • Presacral • Secondary Drainage • Common Iliac • Para-aortic

  12. Metastatic Sites • Lung • Bone • Peritoneum

  13. Physical Exam • Complete • Abnormal findings: • Solid pelvic mass • Induration of prostate • Inguinal adenopathy • Nodularity at periumbilical • Hepatic enlargement

  14. Urologic evaluation • U/A; Urinary Cytology • Evaluation of upper urinary tract • CT abd/pel • EUA/Cystourethroscopy • Detailed description of size, number, appearance, location, and growth pattern • Biopsy/Transurethral resection • Include suspicious lesion, any sites of previous bladder tumor, grossly normal epithelium, prostatic urethra

  15. http://www.emoryhealthcare.org/urology/oncology/bladder-cancer/bladder-cancer-grading-staging.htmlhttp://www.emoryhealthcare.org/urology/oncology/bladder-cancer/bladder-cancer-grading-staging.html

  16. http://seer.cancer.gov/

  17. http://seer.cancer.gov/

  18. T Staging TURBT Surgeon - Pathologic Organ Conservation – Clinical (TURBT: can see understaging)

  19. Histopathologic Type • Urothelial Carcinoma (Transitional Cell) • In Situ • Papillary, Flat, Squamous Differentiation, Glandular Differentiation, Squamous/Glandular Differentiation • Variants: Micropapillary and Nested subtypes • Squamous Cell Carcinoma • Adenocarcinoma • Undifferentiated Carcinoma

  20. Carcinoma in situ http://www.webpathology.com http://www.realwire.com

  21. Urothelial, Low grade

  22. Urothelial, High Grade Johns Hopkins Pathology http://path.upmc.edu/cases/case15/images/gross1.jpg

  23. Management, Superficial Tumors

  24. http://www.rtog.org/members/protocols/0926/0926.pdf Slide adapted from: Shipley, Zeitman. An update of bladder conservation by tri-modality therapy in muscle-invasive cancer. ASTRO Refresher, 2009.

  25. Management: Muscle-Invasive Disease

  26. Treatment Modalities • Local • Surgery • Radical Cystectomy, Lymphadenectomy and Urinary Diversion • Radiation Therapy • Systemic • Chemotherapy • Adjuvant and Neoadjuvant

  27. Radical Cystectomy Technique • Males • Bladder • Prostate • Seminal Vesicles • Females • Bladder • TAH/BSO • Anterior Vagina • Urethra http://www.memhc.org

  28. Urinary Diversion • Incontinent cutaneous • Cutaneous continent • Requires self catheterization of reservoir • Orthotopic neobladder • Segment of bowel attached to urethra • Patients able to voluntarily void

  29. Surgical Outcomes

  30. RFS/OS with Cystectomy Alone

  31. Fig 2. (A) Recurrence-free survival and (B) overall survival in 1,054 patients after radical cystectomy stratified by pathologic stage and lymph node status Stein, J. P. et al. J Clin Oncol; 19:666-675 2001

  32. Stein et al: Organ confined, lymph node negative tumors • 56% pts • 5/10 yr RFS: 82%/85% • No difference in survival • Tis, Ta, T1, T2a, T2b • Supports definitive surgical management for this group

  33. Extravesical, Lymph Node – Negative Tumors • 20% of patients • No survival difference between pT3 and pT4 • 5y/10y RFS: 58%/55% • LN involvement: 45% • Assoc. with higher recurrence, decreased survival

  34. Stein et al.: Lymph Node + • ~25% with path positive nodes • Risk increases with T stage • 33% alive at 5 yrs • Survival predicted by extent of dissection • # nodes sampled • Node Density http://training.seer.cancer.gov

  35. Pelvic Node Dissection • Standard Template • Distal Common Iliac, Obturator, Hypogastric, External Iliac • Extended template • Standard + presacral, common iliac nodes to aortic bifurcation, more proximal to origin of inferior mesenteric • Data suggesting standard template inadequate • 290 patients, mapping studyusing extended template • 28% cases with positive nodes, 25% had nodes restricted to standard template, 25% had all nodes outside standard template

  36. LN staging (2010) • Nx: Nodes not assessed • N1: Single Node in the true pelvis (hypogastric, obturator, external iliac, presacral) • N2: Multiple regional nodes in true pelvis • N3: Common iliac nodes

  37. Surgical Morbidity • General • MI, PE, DVT • Impotence (100%) • Urination • Incontinence (15-40%), Enuresis (30%), Hypercontinence (15%, women), • Sexual Dysfunction • Cavernous nerve injury

  38. Nerve-sparing Surgical Technique http://urology.jhu.edu

  39. Nerve-sparing Surgical Technique • Concern for positive margins • LR ~3-5% • Comparable to patients managed without nerve sparing • Erectile Function • 31-50% patients within one to two years • Most requiring PDE-5 inhibitor • Prostate sparing surgery • Highly selected patients with good outcome • Concern for oncologic efficacy

  40. Recurrence Following Surgery • Correlates well with stage and subgroup • USC experience (Stein et al.) • 30% patients fail locally/distant • Median time to rec. (Any/Local/Distant): 12m/18m/12m • Pelvic recurrence: 7% • 6% with OC tumors • 13% with EV tumors • Nearly all pts succumb • Distant Recurrence: • 13% with OC/LN- • 32% with EV/LN- • 52% with LN+ • 86% recur within 3 years post-op • Need for diligent surveillance

  41. Neoadjuvant Chemotherapy • High risk for distant metastasis in muscle invasive disease • Advantages: • Theoretical benefit in eliminating micrometastases prior to surgery • Can evaluate responsiveness of a lesion • Downstaging • Disadvantages • Discordance between clinical and pathologic staging • Exam suggests CR, but path shows PR • Delay of local therapy

  42. MRC/EORTC • 491 pts, high grade T2-T4a, N0-Nx, M0 urothelial • 3 cycles of cisplatin, methotrexate, vinblastine (MCV) or no chemo followed by RT or cystectomy (institution choice) • pCR (CMV): 33% • Absolute OS improvement of 5.5% for chemo (NS) • 7 yr update (NS)

  43. INT 0080 • 317 pts, T2-4a N0M0 urothelial • Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC) x 3 + cystectomy v. cystectomy alone • F/u 8.7 yrs • pCR 38% v. 15% • MS: 77 mo. v. 46 mo. (p = 0.06) • 5 yr OS: 57% v. 43% (p = 0.06) • 30% with ≥ grade 3 hematologic/GI effects, no treatment related deaths

  44. Retrospective review using SWOG database • Surgical factors have prognostic significance? • Found: optimal cystectomy and lymph node dissection (negative margins and at least 10 node) associated with survival (>80% at 5 yrs) • INT 0080 not designed for this analysis, subject to confounders

  45. Italian Bladder Tumor Study Group • 171 pts, T2-T4, N0, M0 urothelial • Methotrexate, vinblastine, epirubicin, cisplatin (MVEC) + cystectomy v. cystectomy alone • Not published • NS for DFS, OS at 33 mo f/u in prelim report • Clinical staging accurate in 42% • 23% overstaged • 33% understaged

  46. Nordic 1 • 325 pts, high grade T1, or stages T2-T4a, Nx, M0 urothelial • 2 cycles cisplatin/doxorubicin + RT and Cystectomy • 5 yr f/u • OS: 59% v. 51% • Cancer specific survival (CSS): 64% v. 54% • Subset analysis (T3/4): • 15% OS, 20% CSS benefit with chemo

  47. Nordic 2 • Prospectively defined subgroups • 317 pts, T2-T4aNxM0 urothelial • Cisplatin, Methotrexate +cystectomy v. cystectomy alone • 5 yr OS: 53% v. 46% in favor of neoadjuvant (SS)

  48. Metaanalysis Platinum based combination chemo: 13% improvement in relative risk of death

  49. Survival, Combination Chemo

More Related